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Background

Various studies have shown a discordance between aPTT
and Anti-Xa levels in heparinized patients with Left
Ventricular Assisted Devices (LVAD). This discordance
could lead to unwanted clinical outcomes if heparin
therapy is not properly assessed in these high-risk
patients. Patients with LVADs require precise monitoring
to reduce the risk of both thrombus and hemorrhage.
Aurora St. Luke’s Medical Center (ASLMC) currently
utilizes aPTT to routinely monitor heparinized patients.
The goal of this retrospective review is to determine if
aPTT and Anti-Xa levels correlate and represent accurate
heparin serum concentrations.

Primary Objective
•To assess the correlation between aPTT and Anti-Xa
levels based off hospital therapeutic heparin metrics

Secondary Objectives
• To assess the correlation of aPTT and Anti-Xa levels
in the setting of elevated LDH (>600) or an INR >
1.5.

Results

22 patients with 191 serial paired Anti-Xa and PTT levels were included for analysis. The mean age at implant was 54.5 +/13.3, 17 (77.3%) were male, and 19 (81.8%) of implants were destination therapy. The majority of the LVADs were
implanted in 2018, 2019, and 2020 (6 (27.3%), 3 (13.6%), and 8 (36.4%), respectively) with 14 (63.6%) received
HeartMate 3, 3 (13.6%) received HeartMate II, and 5 (22.7%) received HeartWare implants. Of the 191 levels, 42 (22%)
were indicated as sub-therapeutic by both PTT (<45) and Anti-Xa (<0.3), 82 (43%) were indicated as therapeutic by PTT
(45-70) but sub-therapeutic by Anti-Xa, 37 (19%) were indicated as therapeutic by both PTT and Anti-Xa, and 2 (1%) were
indicated as supra-therapeutic by both PTT and Anti-Xa (Table 1) (Kappa Estimate=0.1, 95% CI=(0.01-0.18)). Agreement is
similar for those labs where INR>1.5 and INR<=1.5. Figure 1 displays the level of discordance as a function of Anti-Xa vs
PTT. A stronger correlation between the serial levels would yield a more linear relationship upon the scatterplot.
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Methods
Retrospective observational assessment of patients
with LVADs treated with therapeutic intravenous
heparin

Anti-Xa

A simple Kappa Estimate was used to calculate
agreement between Anti-Xa and PTT group levels.
The project was not determined to be Human Subject
Research and did not require institutional review board
(IRB) oversight.

Therapeutic groupings indicated by PTT levels were in slight
agreement when compared with Anti-Xa. The most common
disagreement group was where PTT indicated a therapeutic
range and Anti-Xa indicated sub-therapeutic. In our
institution, the PTT tended to overestimate the
concentrations of Heparin in the body. Overestimating
heparin concentrations can theoretically place patients at a
higher risk underdosing their anticoagulation. As LVAD
patients are already at a higher risk of thrombosis, this
relationship is less than ideal. However, the risk of bleeding
is also a cause for concern as a switch to Anti-Xa monitoring
would theoretically lead to larger doses of heparin in order
to reach therapeutic level. Further studies are required to
determine the consequences of this discordance.
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. Serial paired levels of Anti-Xa and PTT were monitored
and analyzed
Categorical variables were described using frequency
and percentages and continuous variables were
described using means and standard deviations or
medians and interquartile ranges
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